Ultrathin Biodegradable-Polymer Orsiro Drug-Eluting Stent Performance in Real Practice Challenging Settings.
Rigatelli G, Zuin M, Gianese F, Adami D, dell'Avvocata F, Barison S, Mazza A, Picariello C, Roncon L.
Cardiovasc Revasc Med. 2021 Sep;30:12-17. doi: 10.1016/j.carrev.2020.09.027. Epub 2020 Sep 23.
Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease.
Xin X, Wang X, Dong X, Fan Y, Shao W, Lu X, Xiao P.
Sci Rep. 2019 May 13;9(1):7268. doi: 10.1038/s41598-019-43681-x.
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial.
Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel MA, O'Leary N, Sharif F, Möllmann H, Reiber JHC, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys PW.
EuroIntervention. 2020 Dec 18;16(12):e997-e1004. doi: 10.4244/EIJ-D-20-00772.
Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease.
Yang ZK, Shen WF, Zhang RY, Kong Y, Zhang JS, Hu J, Zhang Q, Ding FH.
J Interv Cardiol. 2007 Feb;20(1):10-6. doi: 10.1111/j.1540-8183.2007.00222.x.
Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting: A Pooled Analysis of Serial PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) Studies.
Lee PH, Lee JY, Lee CW, Kim SO, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ.
Circ Cardiovasc Interv. 2018 Jan;11(1):e005374. doi: 10.1161/CIRCINTERVENTIONS.117.005374.
Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance.
Seung KB, Kim YH, Park DW, Lee BK, Lee CW, Hong MK, Kim PJ, Chung WS, Tahk SJ, Park SW, Park SJ.
J Am Coll Cardiol. 2005 Sep 6;46(5):787-92. doi: 10.1016/j.jacc.2005.06.009.
Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease).
Colombo A, Chieffo A.
Circulation. 2007 Sep 18;116(12):1424-32. doi: 10.1161/CIRCULATIONAHA.106.621359.
Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome.
Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU.
J Thorac Cardiovasc Surg. 2006 May;131(5):956-62. doi: 10.1016/j.jtcvs.2005.10.058. Epub 2006 Apr 27.
Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use.
Park KH, Kim U, Lee CH, Son JW, Park JS, Shin DG, Kim YJ, Cho JH.
Korean J Intern Med. 2016 Jul;31(4):678-84. doi: 10.3904/kjim.2015.045. Epub 2016 Mar 25.
Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry.
Sheiban I, Sillano D, Biondi-Zoccai G, Moretti C, Garrone P, Lombardi P, Sciuto F, Omedè P, Iacovino C, Spina CL, Trevi GP.
J Cardiovasc Med (Hagerstown). 2009 Jun;10(6):461-8. doi: 10.2459/JCM.0b013e3283293483.
